Best Liver cancer stage 4 doctors in Israel: TOP 12 doctors

Professor Ofer Merimsky leads the oncology department at Tel Aviv Medical Center, with over 41 years of experience of experience in treating advanced cancers.

• Specializes in metastatic liver cancer and soft tissue tumors
• Fellowship-trained in Paris for bone and soft tissue oncology
• Active member of ESMO Sarcoma group and ASCO
• Published extensive research on cancer treatment outcomes

Dr. Pelles Sharon specializes in advanced liver cancer treatments at Sourasky Medical Center, including innovative therapies like SIRT and HIPEC.

• Offers comprehensive liver cancer treatments including chemotherapy and immunotherapy
• Performs liver resections and radiofrequency ablations
• Participates in clinical research on cancer treatments
• Provides targeted therapy and chemoembolization for liver cancer

44 years of experience specializing in liver and GI cancers – he leads the Cancer Prevention Center at Tel Aviv's Sourasky Medical Center.

• Publishes groundbreaking research on gene therapy for liver and GI tumors
• Author of over 300 scientific papers on cancer detection and treatment
• Trained in the US at the prestigious NewYork-Presbyterian Center
• Active member of the European Society of Digestive Oncology
• Head of the Cancer Prevention Center since 2002

Dr. Einat Shacham‑Shmueli is a senior medical oncologist at the Gastrointestinal Clinic, Cancer Center, Sheba Medical Center. She treats cancers of the colon, stomach, and pancreas. She also manages metastatic disease. She uses precision diagnostics and biomarkers, systemic therapies, and radiotherapy. Care is provided within a multidisciplinary team.

She has authored more than 25 peer‑reviewed papers on GI oncology, tumor biology, and new treatments. Her work includes studies on stenting for malignant colonic obstruction. She serves as an investigator in international programs, including the NCI, the Radiation Therapy Oncology Group, and the Cancer Therapy Evaluation Program.

Education: MD, Tel Aviv University. Oncology residency, Tel Aviv Sourasky Medical Center. Advanced training in GI oncology, UCSF. Accreditations: Board certified in Oncology and Gastroenterology. Member, Israel Society of Oncology and Radiotherapy.

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Heads the Medical Oncology Division at Sourasky Medical Center – a key leader for a complex condition.

• Extensive experience in treating liver cancer stage 4
• Specializes in Medical Oncology and Internal Medicine
• Medical degree from Ben Gurion University of the Negev
• Provides full evaluations to build a comprehensive treatment plan

Over 35 years of experience performing complex abdominal surgery – Dr. Greenberg is a top specialist in open and minimally invasive Whipple procedures at Sourasky Medical Center.

• Heads the Colorectal Surgery Department
• Expert in both open and minimally invasive techniques
• Treats a wide range of abdominal cancers

32 years of experience specializing in liver and pancreatic cancers – Dr. Ben-haim is among Israel's top gastrointestinal oncology surgeons at Sourasky Medical Center.

• Expert in Whipple surgery for complex cases
• Focuses exclusively on gastrointestinal cancers
• Performs advanced interventions for cancer management

Head of the Gastrointestinal Cancer Center at Hadassah Medical Center – directly oversees complex liver cancer cases. His 33-year career is entirely focused on oncology and radiotherapy.

• Board-certified in both medical oncology and radiotherapy
• Trained and built his career at Hadassah University Hospital in Jerusalem
• Active member of the national Committee for Gastrointestinal Cancer
• Experienced in the latest systemic therapies and targeted radiation
• Senior physician role involved in training other oncologists

Dr. Alexander Beny leads the Gastrointestinal Malignant Service at Rambam Medical Center, specializing in advanced liver cancer cases.

• Board-certified oncologist with extensive training in medical and radiation oncology
• Director of gastrointestinal oncology services at a major Israeli hospital
• Completed specialized training in modern brachytherapy techniques
• Fluent in English and Hebrew for international patients

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.